Literature DB >> 6976850

Toxicology of the 8-aminoquinolines and genetic factors associated with their toxicity in man.

P E Carson, R Hohl, M V Nora, G W Parkhurst, T Ahmad, S Scanlan, H Frischer.   

Abstract

In vitro studies on primaquine have been carried out to examine its ability to stimulate the oxidative pathway of glucose metabolism in human erythrocytes and in vivo studies were carried out after ingestion of the drug to determine plasma levels and to investigate the formation of metabolites and the effects of the drug on human erythrocytes. These investigations showed that:1) Two mechanisms are involved in the stimulation of the oxidative pathway. This was demonstrated by comparing the effects of methylene blue, ascorbic acid, primaquine, and other drugs on normal, glutathione-reductase-deficient, and G6PD-deficient erythrocytes. A start was made towards classifying drugs according to the mechanism by which they stimulate CO(2) production.2) Following oral ingestion of primaquine, three as yet unidentified metabolites were present, two in the plasma and one in the urine. The rapid disappearance of primaquine from the plasma (within 24 hours) was confirmed.3) Two factors that stimulate glucose oxidation in human erythrocytes were found in plasma; one occurred only in fresh plasma, when EDTA was present, and the other occurred in all plasma and serum samples studied.4) The erythrocytes of blood drawn 24 hours after the ingestion of primaquine (after primaquine had disappeared from the plasma) showed increased ability to oxidize glucose.It is not yet known whether serum or plasma prepared from blood drawn 24 hours after ingestion of primaquine has the ability to increase the oxidation of glucose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6976850      PMCID: PMC2396066     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  14 in total

1.  Enzymatic deficiency in primaquine-sensitive erythrocytes.

Authors:  A S ALVING; P E CARSON; C L FLANAGAN; C E ICKES
Journal:  Science       Date:  1956-09-14       Impact factor: 47.728

2.  Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine.

Authors:  A S ALVING; J ARNOLD; R S HOCKWALD; C B CLAYMAN; R J DERN; E BEUTLER; C L FLANAGAN
Journal:  J Lab Clin Med       Date:  1955-08

3.  THE TOXICITY OF LARGE DOSES OF PENTAQUINE (SN-13,276), A NEW ANTIMALARIAL DRUG.

Authors:  B Craige; L Eichelberger; R Jones; A S Alving; T N Pullman; C M Whorton
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

4.  A STUDY OF THE PROPHYLACTIC EFFECTIVENESS OF SEVERAL 8-AMINOQUINOLINES IN SPOROZOITE-INDUCED VIVAX MALARIA (CHESSON STRAIN).

Authors:  R Jones; B Craige; A S Alving; C M Whorton; T N Pullman; L Eichelberger
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

5.  Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea].

Authors:  H Frischer; T Ahmad
Journal:  J Lab Clin Med       Date:  1977-05

Review 6.  Glucose-6-phosphate dehydrogenase deficiency and related disorders of the pentose phosphate pathway.

Authors:  P E Carson; H Frischer
Journal:  Am J Med       Date:  1966-11       Impact factor: 4.965

7.  Haemolytic effect of two sulphonamides evaluated by a new method.

Authors:  G D Gaetani; C Mareni; R Ravazzolo; E Salvidio
Journal:  Br J Haematol       Date:  1976-02       Impact factor: 6.998

8.  Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report.

Authors:  A S ALVING; C F JOHNSON; A R TARLOV; G J BREWER; R W KELLERMEYER; P E CARSON
Journal:  Bull World Health Organ       Date:  1960       Impact factor: 9.408

9.  The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes.

Authors:  A L Sagone; G M Burton
Journal:  Am J Hematol       Date:  1979       Impact factor: 10.047

10.  A selected ion monitoring assay for primaquine in plasma and urine.

Authors:  J Greaves; D A Price-Evans; H M Gilles; J D Baty
Journal:  Biomed Mass Spectrom       Date:  1979-03
View more
  10 in total

Review 1.  The evolution of tafenoquine--antimalarial for a new millennium?

Authors:  W Peters
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

2.  Selective toxicity of the antimalarial primaquine-evidence for both uncoupling and inhibitory effects of a metabolite on the energetics of mitochondria and its ATP synthase complex.

Authors:  J K Baker; J M Hullihen; P L Pedersen
Journal:  Pharm Res       Date:  1986-10       Impact factor: 4.200

Review 3.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

4.  Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.

Authors:  Jian Guan; Quan Zhang; Michael O'Neil; Nicanor Obaldia; Arba Ager; Lucia Gerena; Ai J Lin
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 5.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Recommendations for patients traveling.

Authors:  E C Jong; M Southworth
Journal:  West J Med       Date:  1983-05

7.  Novel sulfur-containing microbial metabolite of primaquine.

Authors:  C D Hufford; J K Baker; J D McChesney; A M Clark
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 8.  Adverse effects of antimalarials. An update.

Authors:  G A Luzzi; T E Peto
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

Review 9.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Tafenoquine for travelers' malaria: evidence, rationale and recommendations.

Authors:  J Kevin Baird
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.